ASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma
Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.